http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2534513-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17e6c778a71c468773a533a0b4dcd1e8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-01088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-04 |
| filingDate | 2009-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e58e4489065ee789edc09d38e040b9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_467b107b1848ebccd0c042f0de9e0010 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e2f0adcefbb51703fc30a261f49222b |
| publicationDate | 2015-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2534513-T3 |
| titleOfInvention | Peptides derived from HMG-CoA reductase and cosmetic and / or pharmaceutical composition containing them |
| abstract | Peptide derived from human HMG-CoA reductase, of general formula (I) R1- (AA) n-X1-Gly-Lys-X2- (AA) p-R2 Wherein X1 is lysine or arginine or any amino acid , X2 is serine or threonine, AA represents any amino acid, or one of its derivatives, and n and p are integers between 0 and 4, R1 represents the primary amine function of the N-terminal amino acid, free or substituted by a protecting group which can be selected from an acetyl group, a benzoyl group, a tosyl group or a benzyloxycarbonyl group, R 2 represents the hydroxyl group of the carboxyl function of the C-terminal amino acid, free or substituted by a protecting group which can be selected from an alkyl chain C1 to C20, or an NH2, NHY or NYY group with Y representing a C1 to C4 alkyl chain. characterized in that the peptide is selected from the following sequences: (SEQ ID No. 1) Glu-Gly-Lys-Gly-Lys-Ser-Val-Val-Cys-Glu (SEQ ID No. 2) Glu-Gly-Lys- Gly-Lys-Ser-Val-Val (SEQ ID No. 3) Asp-Gly-Lys-Gly-Lys-Thr (SEQ ID No. 4) Arg-Gly-Lys-Ser (SEQ ID No. 5) Arg- Gly-Lys-Ser-NH2 (SEQ ID No. 6) Arg-Gly-Lys-Thr (SEQ ID No. 7) Arg-Gly-Lys-Thr-NH2 (SEQ ID No. 8) Lys-Gly-Lys- Ser (SEQ ID No. 9) Lys-Gly-Lys-Ser-NH2 (SEQ ID No. 10) Gly-Lys-Ser-NH2. |
| priorityDate | 2008-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 180.